Securities Code: 002898
Securities Abbreviation: Sailong Delisting
Announcement Number: 2026-076
Sailong Pharmaceutical Group Co., Ltd.
Fourth Risk Warning Announcement on Company Shares Entering Delisting Transaction Period
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or significant omissions.
Special Risk Warning:
-
Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") shares will be delisted on the trading day following the expiration of the delisting transaction period, and the company's shares will be terminated from listing.
-
The Company's shares resumed trading and entered the delisting transaction period on June 26, 2026. The delisting transaction period is fifteen trading days, with the expected last trading day being July 16, 2026. This announcement is made on the eleventh trading day. With four remaining trading days, the shares will be terminated from listing upon the expiration of the trading period. Investors are urged to invest prudently and be aware of the risks.
-
During the trading period of the Company's shares in the delisting transaction period, the Company will not plan or implement any major asset restructuring.
-
Investors, securities companies, and other market participants are requested to promptly settle stock pledge repurchase, agreed repurchase, margin financing, securities lending, and other businesses before the stock delisting.
-
For judicial freeze businesses that expire after the stock delisting and before the initial registration period of the two-network company and delisted company board (hereinafter referred to as the "Delisting Board") established and managed by Shenzhen Securities Transfer Co., Ltd. on behalf of the original securities company, it is recommended that the competent authorities handle the renewal of the freeze through the original assisting execution channels before the stock delisting.